Novo Nordisk stock
Novo Nordisk stock Articles
Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. With promising new treatments in the pipeline, 24/7 Wall St. projects huge upside through the end of the decade.
Published:
